share_log

华润双鹤(600062.SH):部分产品获得药品补充申请批准通知书及化学原料药上市申请批准通知书

China Resources Double-Crane Pharmaceutical (600062.SH): Some products have obtained supplementary drug application approval letters and chemical raw materials market application approval letters.

Gelonghui Finance ·  Jul 9 05:09

China Resources Double-Crane Pharmaceutical (600062.SH) announced on July 9th that it has received the Drug Supplement Approval Notice for Aminophylline Injection from the National Medical Products Administration. Its wholly-owned subsidiary, Shuanghe Pharmaceutical (Shangqiu) Co., Ltd., received the Approval Notice for Active Pharmaceutical Ingredient Market Authorization Application from the NMPA.

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Write a comment